Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sandoz’s Erelzi: Biosimilar Pediatric Labeling Strayed From Enbrel

Apr 20 2017

• By Sue Sutter

Related Content

Erelzi Clinical Development Timeline

Apr 20 2017

Biosimilar Sponsors Took Delivery Device Shortcuts For Erelzi, Amjevita

Apr 20 2017

Enbrel REMS delays pediatric approval

Aug 04 2008

Biosimilar Labeling Dissected: Sandoz’s <em>Zarxio</em> Uses Amgen’s Neupogen Text

Mar 09 2015

FDA Committee Recommends Amgen’s Enbrel For Approval In Pediatric Psoriasis

Jun 18 2008

Biosimilar Labeling Variation From Reference Product OK, FDA Says

Apr 04 2016

With Inflectra, FDA Showed Flexibility On Biosimilar Pediatric Study Plans

Jul 15 2016

Biosimilars' Pediatric Pressures Could Push Them Toward Interchangeability

Jul 15 2016

Sandoz Steers Enbrel Biosimilar Away From Equivalence Quandary With Reanalysis

Jul 11 2016

FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi

Aug 31 2016

Related Companies

Novartis AG

Amgen, Inc.

Novartis AG

AbbVie Inc.

Celltrion, Inc.

Johnson & Johnson

Additional Topics

United States Biosimilars Regulation Drug Review Profile BioPharmaceutical Dermatology Inflammation

More from Drug Review Profiles

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window